MedWatch

Fruergaard on Novo streamlinings: "Obviously, we will see layoffs"

CEO in Novo Nordisk, Lars Fruergaard Jørgensen, will not conduct a coordinated cost-cutting round in the company. However, he does not dismiss a workforce reduction. It is necessary for maximizing the company's growth opportunities. "We must aim higher," he says.

Foto: /Ritzau Scanpix/Asger Ladefoged/

A comprehensive and coordinated cost-cutting round is not under way in Danish drug group Novo Nordisk, and CEO Lars Fruergaard Jørgensen disproves the rumor of up to 3000 job eliminations across the organization.

According to the CEO, such a round of job cuts was never under consideration. However, firings are coming up.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Headhunter: Afgående Leo-boss var et flop

Det var et fejlskud at ansætte Catherine Mazzacco som adm. direktør for Leo Pharma, vurderer headhunter, der ser afgangen som et naturligt skridt forud for børsnoteringen af Leo Pharma. Til at styre den proces i mål vil bestyrelsen efter alt at dømme skulle til udlandet for at finde den rette profil, lyder det videre.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier